Le Lézard
Classified in: Health, Science and technology, Business
Subject: TNM

Shanghai ChemPartner Announces Merger Deal Closure with Quantum


SHANGHAI, Aug. 16, 2018 /PRNewswire/ -- Shanghai ChemPartner, a leading life science organization providing high-quality and cost-effective drug discovery and development  services, announced the closure of the merger deal with Quantum Hi-Tech China Biological.

Quantum, in a press release in 2017, announced their intent to join with Shanghai ChemPartner, a science-drive, technology-based Contract Research and Contract Manufacturing Organization (CRO/CMO) serving the pharmaceutical and biotechnology industry worldwide. The merger and corporate restructuring were also addressed by ChemPartner in a press release in March 2017, and are part of the Company's plans to leverage the capital market in China.

"We are excited to join with Quantum, and together achieve our vision and goals as a public company. This significant milestone was achieved as a result of hard work and rigorous due diligence. The successful outcome and approval of our merger provide confidence in the bright future ahead for ChemPartner, our employees and our clients," stated Michael Hui, Chairman of Shanghai ChemPartner.

Michael Hui will remain the Chairman of the Shanghai ChemPartner, and will serve as the Vice Chairman of the Quantum Board of Directors.  The ChemPartner leadership team will remain intact, and the company will continue to operate as a standalone entity. 

Shanghai ChemPartner, which includes ChemPartner, China Gateway Pharmaceutical Development, China Gateway Biologics, and ChemExplorer, offers a broad range of drug discovery and development capabilities including biologics discovery, chemistry and medicinal chemistry, biology and pharmacology, DMPK and exploratory toxicology, and small and large molecule CMC.  Shanghai ChemPartner serves a diverse global client base and has laboratories, business offices and representatives in the US, Europe, China, and Japan.

SOURCE Shanghai ChemPartner


These press releases may also interest you

at 06:15
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Exciting technical...

at 06:10
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The 2-year grant...

at 06:08
Aesthetic Management Partners LLC, a manufacturer of skin-based solutions and a provider of energy-based devices announces its collaboration with Croma (Croma-Pharma® GmbH), a global player in the minimally invasive aesthetics market and a leading...

at 06:05
The 2023 U.S. soybean field trials conducted by Texas Crop Science (TCS) demonstrated an average yield increase of 21% in soybean lines incorporating the TCS yield trait. This breakthrough in performance would generate approximately $121 per acre in...

at 06:05
3EO Health, a "Point of Life" diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable. Today, the company has published...

at 06:05
Zura Bio Limited ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights. The Company has also...



News published on and distributed by: